ArticleJournal of cellular physiology2026
Zhenwu Decoction Alleviates Renal Fibrosis by Disrupting the Bidirectional Crosstalk Between TGF-β/Smad and Notch Signaling.
Article in Journal of cellular physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Zhenwu Decoction Alleviates Renal Fibrosis by Disrupting the Bidirectional Crosstalk Between TGF-β/Smad and Notch Signaling.Journal of cellular physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Zhenwu Decoction (ZWD) is a traditional Chinese medicine prescription with well-documented renoprotective effects, though its precise mechanism of action against renal fibrosis remains to be elucidated. This study aimed to explore whether ZWD mitigates renal fibrosis by modulating the loop of transforming growth factor-β (TGF-β)/Smad and Notch signaling pathways. In vivo and in vitro experiments were conducted using unilateral ureteral obstruction (UUO) rat models and TGF-β1-stimulated NRK-49F fibroblast cells, respectively. The study's findings revealed that ZWD significantly improved renal function, mitigated pathological damage, and decreased extracellular matrix deposition in UUO rats. Treatment with ZWD led to a marked downregulation of TGF-β1, Notch1, and Jagged1 expression, as well as a reduction in Smad2/3 phosphorylation, both in vivo and in vitro. Gain- and loss-of-function experiments demonstrated that overexpression of TGF-β1 enhanced Notch signaling, whereas TGF-β1 knockdown inhibited it. Similarly, Notch1 overexpression increased TGF-β/Smad signaling, while Notch1 silencing suppressed TGF-β/Smad activity, thus confirming the existence of a positive bidirectional feedback loop in the context of renal fibrosis. Importantly, Notch1 overexpression directly induced a fibrotic phenotype in NRK 49F cells. In summary, the TGF-β/Smad and Notch pathways constitute a bidirectional positive feedback loop that promotes renal fibrosis. ZWD alleviates renal fibrosis by disrupting this crosstalk, highlighting its potential as a therapeutic strategy for chronic kidney disease (CKD).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.